ASCO 2025 | How can we overcome anti-PD-1 resistance in melanoma?
Gino In
• 30 May 2025
Gino In, MD, MPH, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, briefly shares his insights on the emerging strategies aiming to improve outcomes for patients with checkpoint-refractory melanoma. Promising approaches utilizing alternative mechanisms of action include oncolytic viruses, tumor-infiltrating lymphocytes, and bispecific antibodies. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
